首页> 外文期刊>Indian journal of cancer. >Role of chemoradiation in advanced cervical cancer.
【24h】

Role of chemoradiation in advanced cervical cancer.

机译:化学放疗在晚期宫颈癌中的作用。

获取原文
获取原文并翻译 | 示例
       

摘要

A prospective randomized study was conducted in our department of Radiotherapy, Regional Institute of Medical Sciences, Imphal to evaluating the role of chemoradiation in the management of advanced inoperable cervical cancer (stage IIB-IIIB) taking only radiation treatment as control spanning the period 1996-1999. Of the fifty patients accumulated in the study group, three patients did not complete treatment, one expired due to other causes and three were lost to follow up. Likewise, of the forty-six patients in the control group, one patient did not complete treatment and 4 were lost to follow up. Thus only 43 and 41 patients were available for the result analysis for the study and control groups respectively. The early treatment response as assessed after two months of treatment conclusion were 79.1%, 13.9%, 93.0% and 58.5%, 31.7%, 90.2% as complete response (CR), partial response (PR), and total response (TR) respectively for the study and control groups. Our patients included in this study had a median follow up of 35 months and 33 months for study and control groups respectively. For this follow up, the disease-free survival, survival with disease and overall survival were 67.4%, 7.0%, 74.4% and 43.9%, 12.2%, 56.1% for study and control groups respectively. There was an increase in early side-effects in the chemoradiation group but the difference was not significant. Because of the early side effects, treatment delays ensued in 7 patients (16.3%) and in 3 patients (7.3%) in the study and control groups respectively. There was no significant increase in the late treatment toxicities in both the groups.
机译:我们在Imphal地区放疗科进行了一项前瞻性随机研究,以评估化学放疗在晚期不能手术的宫颈癌(IIB-IIIB期)管理中的作用,仅以放射治疗为对照,时间跨度为1996- 1999年。在研究组累积的50名患者中,有3名患者未完成治疗,其中1名因其他原因而死亡,3名失去随访。同样,在对照组的46例患者中,有1例患者没有完成治疗,有4例失访。因此,分别只有43和41位患者可用于研究组和对照组的结果分析。在结束治疗两个月后评估的早期治疗反应分别为完全缓解(CR),部分缓解(PR)和总缓解(TR)的分别为79.1%,13.9%,93.0%和58.5%,31.7%,90.2%为研究和对照组。研究组和对照组的患者中位随访时间分别为35个月和33个月。对于本次随访,研究组和对照组的无病生存率,有病生存率和总生存率分别为67.4%,7.0%,74.4%和43.9%,12.2%,56.1%。化学放疗组早期副作用增加,但差异不显着。由于早期副作用,在研究组和对照组中分别有7例患者(16.3%)和3例患者(7.3%)出现了治疗延迟。两组的后期治疗毒性均没有显着增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号